Eiger BioPharmaceuticals Valuation Multiples
Discover Eiger BioPharmaceuticals' revenue and EBITDA valuation multiples and M&A history.
Eiger BioPharmaceuticals Overview
About Eiger BioPharmaceuticals
Eiger BioPharmaceuticals Inc is a commercial stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.
Founded
2000
HQ
Employees
25
Website
Financials (FY)
EV
$4M
Valuation Multiples
Start free trial
Eiger BioPharmaceuticals Financials
Eiger BioPharmaceuticals reported last fiscal year revenue of $16M and negative EBITDA of ($71M).
In the same fiscal year, Eiger BioPharmaceuticals generated $16M in gross profit, ($71M) in EBITDA losses, and had net loss of ($75M).
Eiger BioPharmaceuticals P&L
In the most recent fiscal year, Eiger BioPharmaceuticals reported revenue of $16M and EBITDA of ($71M).
Eiger BioPharmaceuticals is unprofitable as of last fiscal year, with gross margin of 100%, EBITDA margin of (453%), and net margin of (475%).
Financial data powered by Morningstar, Inc.
Eiger BioPharmaceuticals Stock Performance
Eiger BioPharmaceuticals has current market cap of $10M, and enterprise value of $4M.
Eiger BioPharmaceuticals' stock price is $7.00.
Eiger BioPharmaceuticals has an EPS (earnings per share) of $-50.62.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4M | $10M | 0.0% | - | - | - | $-50.62 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEiger BioPharmaceuticals Valuation Multiples
Eiger BioPharmaceuticals trades at 0.3x EV/Revenue multiple, and (0.1x) EV/EBITDA.
Eiger BioPharmaceuticals Financial Valuation Multiples
As of August 23, 2026, Eiger BioPharmaceuticals has market cap of $10M and EV of $4M.
Eiger BioPharmaceuticals has a P/E ratio of (0.1x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Eiger BioPharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Eiger BioPharmaceuticals Margins & Growth Rates
In the most recent fiscal year, Eiger BioPharmaceuticals reported gross margin of 100%, EBITDA margin of (453%), and net margin of (475%).
Eiger BioPharmaceuticals Margins
Data powered by FactSet, Inc. and Morningstar, Inc.
Eiger BioPharmaceuticals Operational KPIs
Eiger BioPharmaceuticals' revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $3.5M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Eiger BioPharmaceuticals Competitors
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
This data is available for Pro users. Sign up to see all Eiger BioPharmaceuticals competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Eiger BioPharmaceuticals
Eiger BioPharmaceuticals has acquired 1 company to date.
Last acquisition by Eiger BioPharmaceuticals was on November 18th 2015. Eiger BioPharmaceuticals acquired Celladon for $60M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Eiger BioPharmaceuticals
| Description | Celladon is a La Jolla-based clinical-stage biopharma focused on gene therapies for heart failure. The company advances MYDICAR, an AAV1.SERCA2a vector delivered via intracoronary infusion to restore cardiac function. Celladon completed Phase IIb trials in 2015 showing symptom improvements in advanced patients. Founded in 2004, it collaborates with academic centers in California. |
| HQ Country |  |
| HQ City | San Diego, CA |
| Deal Date | 18 Nov 2015 |
| Valuation | $60M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Eiger BioPharmaceuticals acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Eiger BioPharmaceuticals
| When was Eiger BioPharmaceuticals founded? | Eiger BioPharmaceuticals was founded in 2000. |
| Where is Eiger BioPharmaceuticals headquartered? | Eiger BioPharmaceuticals is headquartered in United States. |
| How many employees does Eiger BioPharmaceuticals have? | As of today, Eiger BioPharmaceuticals has over 25 employees. |
| Is Eiger BioPharmaceuticals publicly listed? | Yes, Eiger BioPharmaceuticals is a public company listed on Stuttgart Stock Exchange. |
| What is the stock symbol of Eiger BioPharmaceuticals? | Eiger BioPharmaceuticals trades under 72C ticker. |
| When did Eiger BioPharmaceuticals go public? | Eiger BioPharmaceuticals went public in 2020. |
| Who are competitors of Eiger BioPharmaceuticals? | Eiger BioPharmaceuticals main competitors include |
| What is the current market cap of Eiger BioPharmaceuticals? | Eiger BioPharmaceuticals' current market cap is $10M. |
| What is the current revenue of Eiger BioPharmaceuticals? | Eiger BioPharmaceuticals' last fiscal year revenue is $16M. |
| What is the current EV/Revenue multiple of Eiger BioPharmaceuticals? | Current revenue multiple of Eiger BioPharmaceuticals is 0.3x. |
| Is Eiger BioPharmaceuticals profitable? | No, Eiger BioPharmaceuticals is not profitable. |
| How many companies Eiger BioPharmaceuticals has acquired to date? | As of August 2026, Eiger BioPharmaceuticals has acquired 1 company. |
| What was the largest acquisition by Eiger BioPharmaceuticals? | $60M acquisition of Celladon on 18th November 2015 was the largest M&A Eiger BioPharmaceuticals has done to date. |
| What companies Eiger BioPharmaceuticals acquired? | Eiger BioPharmaceuticals acquired Celladon. |
| In how many companies Eiger BioPharmaceuticals has invested to date? | Eiger BioPharmaceuticals hasn't invested in any companies yet (or none have been disclosed publicly). |
Lists including Eiger BioPharmaceuticals
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.